Sight Sciences, Inc., based in the United States, is a Healthcare company with a high-risk ESG score of 30.8. Specializing in ophthalmic medical devices, Sight Sciences focuses on developing and commercializing innovative technologies for treating common eye diseases. Their product portfolio includes the OMNI Surgical System for glaucoma treatment and the TearCare System for dry eye management. The company generates significant revenue from their Surgical Glaucoma segment.